Phase II Study of Sacituzumab Tirumotecan in Combination With Osimertinib for Neoadjuvant Treatment in Patients With Resectable Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
Clinical trial NCT07329322 · RECRUITING
Trial details
- NCT number
- NCT07329322
- Sponsor
- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-03-30
- Primary completion
- 2027-08-31
- Enrollment
- 30
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.